---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019262"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:58:48.018858+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics Q1 net loss $9.4M; going concern substantial doubt

## Summary
- Net loss of $9.4M ($3.38/share) vs net income of $1.7M in Q1 2023.
- Cash, cash equivalents, and restricted cash total $8.8M as of March 31, 2024.
- Company states cash not sufficient for 12 months, raising substantial doubt about going concern.
- Juvenescence line of credit increased by $2.4M in March and $525k in May; total owed $10.4M.
- Lead candidate SER-252 IND submission planned for 2025; Dr. Simba Gill appointed Executive Chairman.

## SEC filing metadata
- accession: 0001493152-24-019262
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/0001493152-24-019262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019262
- JSON: https://secwatch.observer/filing/0001493152-24-019262.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019262.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively, net income $9.4 million, or ($3.38) per share (basic and diluted), EPS ($3.38) per share (basic and diluted).
  - Period: the quarter ended March 31, 2024
  - Revenue: $5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively
  - Net income: $9.4 million, or ($3.38) per share (basic and diluted)
  - EPS: ($3.38) per share (basic and diluted)
  - Result: reported results
  source text: On May 14, 2024, the Company announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/0001493152-24-019262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.